Last C$14.29 CAD
Change Today -1.34 / -8.57%
Volume 463.4K
CPH On Other Exchanges
As of 4:00 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

cipher pharmaceuticals inc (CPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/19/14 - C$19.53
52 Week Low
03/18/14 - C$7.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cipher pharmaceuticals inc (CPH) Related Businessweek News

No Related Businessweek News Found

cipher pharmaceuticals inc (CPH) Details

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company that commercializes novel formulations of marketed molecules. The company focuses on in-licensing differentiated products, advancing them through the clinical development and regulatory approval stages, and either out-licensing to marketing partners or, in the case of the Canadian market, the company may market the product. Its products include a fenofibrate formulation marketed in the United States as Lipofen; an extended-release tramadol, which is marketed in the United States as ConZip and in Canada as Durela; and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica and in Canada as Epuris. The company also has the exclusive Canadian rights to market the Betesil Patch, a medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis. It has a collaborative partnership with Galephar Pharmaceutical Research, Inc. Cipher Pharmaceuticals Inc. was founded in 2000 and is based in Mississauga, Canada.

Founded in 2000

cipher pharmaceuticals inc (CPH) Top Compensated Officers

Chief Financial Officer and Secretary
Total Annual Compensation: C$235.6K
Vice President of Marketing and Sales
Total Annual Compensation: C$185.8K
Compensation as of Fiscal Year 2013.

cipher pharmaceuticals inc (CPH) Key Developments

Cipher Pharmaceuticals Inc. Reports Revenue Results for the Fourth Quarter and Earnings Results for the Full Year Ended December 31, 2014

Cipher Pharmaceuticals Inc. reported revenue results for the fourth quarter and earnings results for the full year ended December 31, 2014. Total revenue for 2014 was CAD 32.3 million, an increase of 20% compared with CAD 27.0 million in 2013. Net income in 2014 was CAD 20.7 million, or CAD 0.79 per diluted share, compared to net income of CAD 25.0 million, or CAD 0.97 per diluted share in 2013. Income before income taxes was CAD 20.3 million against CAD 18.4 million reported last year. Net cash generated from operating activities was CAD 27.3 million against CAD 7.5 million reported last year. Purchase of property and equipment was CAD 18,000 against CAD 15,000 reported last year. Acquisition of intangible assets was CAD 0.9 million. Adjusted EBITDA rose 12% to a record CAD 22.4 million versus CAD 20.0 million in 2013. In the fourth quarter of 2014, total revenue was CAD 8.5 million, compared with CAD 7.2 million in the same period last year (adjusted for the non-recurring item), an increase of 18%.

Health Canada Accepts for Review of Cipher Pharmaceuticals's Beteflam Patch

Cipher Pharmaceuticals Inc. announced that the Beteflam Patch (previously called the Betesil(R) Patch) has been accepted for review by Health Canada. The Beteflam Patch is a novel, patent-protected, self-adhesive medicated plaster containing 0.1% betamethasone valerate, for the treatment of inflammatory skin conditions such as chronic plaque psoriasis (CPP). Topical corticosteroids remain the primary treatment for steroid-responsive inflammatory skin diseases, including mild to moderate CPP. Occlusion with plastic film dressings is a widely accepted procedure to enhance their efficacy, especially in the treatment of psoriasis. The Beteflam Patch is applied once-daily to the affected region and may be cut to fit the particular size and shape of the psoriatic lesion thereby reducing potential contact of the steroid with healthy areas of skin. The occlusive format of the Beteflam Patch provides a consistent distribution, delivery and absorption of the active ingredient and enhances the potency of the corticosteroid. The patch also helps to moisturize the skin, which accelerates healing and provides a protective barrier that reduces local trauma to the lesion due to scratching and prevents transfer of fluids from the lesion onto clothing. Cipher licensed the Canadian rights to the Beteflam Patch in 2012 from Institut Biochimique SA (IBSA). The efficacy and safety of the product has been established in two successful phase III trials and one successful phase IV trial conducted by IBSA. IBSA recently published positive results from a large non-inferiority study, which compared the product to Dovobet (betamethasone plus calcipotriol), a commonly prescribed combination product containing a corticosteroid and a vitamin D analogue. Acceptance for review by Health Canada resulted in a CAD 150,000 milestone payment from Cipher to IBSA.

Cipher Pharmaceuticals Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 02:00 PM

Cipher Pharmaceuticals Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 02:00 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Shawn Patrick O'Brien, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPH:CN C$14.29 CAD -1.34

CPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.37 USD -0.24
Pfizer Inc $34.32 USD -0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation CPH Industry Range
Price/Earnings 18.4x
Price/Sales 11.3x
Price/Book 5.8x
Price/Cash Flow 17.6x
TEV/Sales 10.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPHER PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at